Notice: This company has been marked as potentially delisted and may not be actively trading. Apricus Biosciences (APRI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends APRI vs. SCPS, VAXX, EVLO, CMRA, ARDS, CALA, MTEM, AMPE, CLVR, and EFTRShould you be buying Apricus Biosciences stock or one of its competitors? The main competitors of Apricus Biosciences include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Molecular Templates (MTEM), Ampio Pharmaceuticals (AMPE), Clever Leaves (CLVR), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "medical" sector. Apricus Biosciences vs. Scopus BioPharma Vaxxinity Evelo Biosciences Comera Life Sciences Aridis Pharmaceuticals Calithera Biosciences Molecular Templates Ampio Pharmaceuticals Clever Leaves eFFECTOR Therapeutics Scopus BioPharma (NASDAQ:SCPS) and Apricus Biosciences (NASDAQ:APRI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership. Does the media prefer SCPS or APRI? In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Apricus Biosciences'average media sentiment score. Company Overall Sentiment Scopus BioPharma Neutral Apricus Biosciences Neutral Does the MarketBeat Community prefer SCPS or APRI? Apricus Biosciences received 228 more outperform votes than Scopus BioPharma when rated by MarketBeat users. However, 100.00% of users gave Scopus BioPharma an outperform vote while only 69.91% of users gave Apricus Biosciences an outperform vote. CompanyUnderperformOutperformScopus BioPharmaOutperform Votes2100.00% Underperform VotesNo VotesApricus BiosciencesOutperform Votes23069.91% Underperform Votes9930.09% Which has higher valuation and earnings, SCPS or APRI? Apricus Biosciences has higher revenue and earnings than Scopus BioPharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioScopus BioPharmaN/AN/A-$11.61MN/AN/AApricus Biosciences$5.76M0.00$320K-$0.990.00 Do institutionals and insiders hold more shares of SCPS or APRI? 19.9% of Apricus Biosciences shares are owned by institutional investors. 5.1% of Scopus BioPharma shares are owned by company insiders. Comparatively, 2.3% of Apricus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is SCPS or APRI more profitable? Scopus BioPharma's return on equity of 0.00% beat Apricus Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Scopus BioPharmaN/A N/A N/A Apricus Biosciences N/A -216.45%-153.13% Which has more risk & volatility, SCPS or APRI? Scopus BioPharma has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Apricus Biosciences has a beta of 1.2, meaning that its stock price is 20% more volatile than the S&P 500. SummaryApricus Biosciences beats Scopus BioPharma on 5 of the 9 factors compared between the two stocks. Get Apricus Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APRI vs. The Competition Export to ExcelMetricApricus BiosciencesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$8,000.00$7.08B$5.83B$9.13BDividend YieldN/A2.75%4.75%3.85%P/E Ratio0.006.1426.8119.22Price / Sales0.00250.79428.3269.65Price / CashN/A65.6738.0134.83Price / Book0.006.707.644.62Net Income$320,000.00$138.98M$3.19B$246.06M Apricus Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APRIApricus BiosciencesN/A$0.00flatN/A-100.0%$8,000.00$5.76M0.00N/ASCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009VAXXVaxxinityN/A$0.00flatN/A-99.3%$13,000.00N/A0.0090High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9,000.00N/A0.00120Options VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$630,000.000.002High Trading VolumeARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5,000.00$3.09M0.0030Gap UpHigh Trading VolumeCALACalithera BiosciencesN/A$0.00flatN/A-97.6%$3,000.00N/A0.0060Analyst ForecastNews CoverageMTEMMolecular TemplatesN/A$0.00+66.7%N/A-100.0%$3,000.00$57.31M0.00260AMPEAmpio PharmaceuticalsN/A$0.00-79.0%N/A-99.9%$2,000.00N/A0.0020Analyst ForecastNews CoverageGap DownHigh Trading VolumeCLVRClever LeavesN/A$0.00-50.0%N/A-100.0%$2,000.00$17.42M0.00560Gap DownHigh Trading VolumeEFTReFFECTOR Therapeutics1.0676 of 5 stars$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010Upcoming Earnings Related Companies and Tools Related Companies SCPS Competitors VAXX Competitors EVLO Competitors CMRA Competitors ARDS Competitors CALA Competitors MTEM Competitors AMPE Competitors CLVR Competitors EFTR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:APRI) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apricus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apricus Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APRI Stock Alerts